InstalabH. Pylori Profile
Should you take a H. Pylori Profile test?
This test is most useful if any of these apply to you.
13 biomarkers included
- Helicobacter PyloriConfirms whether the bacterium is actively living in your stomach right now, the finding every other result in the panel builds on.A positive result means active infection worth treating, since even symptom-free carriers face raised long-term ulcer and gastric cancer risk.
- Virulence Factor, babAReads an adhesion gene that helps the bacterium grip the stomach lining and settle in for the long term.babA adds most risk in combination with cagA and vacA, marking strains linked to the highest measured cancer odds.
- Virulence Factor, cagAReads the best-studied aggression gene, an injected bacterial protein tied to stronger inflammation and higher ulcer and cancer risk.A cagA-positive strain signals higher odds of severe gastritis, ulcers, and gastric cancer, though the size of that risk varies by region.
- Virulence Factor, dupAReads the duodenal-ulcer-promoting gene, named for its proposed link to ulcers lower in the digestive tract.dupA hints at a duodenal ulcer tendency, though its link to disease is less consistent than cagA or vacA.
- Virulence Factor, iceAReads a gene the bacterium switches on when it touches stomach-lining cells.An iceA-positive strain has been tied to ulcer disease in some populations, adding context rather than a firm verdict.
- Virulence Factor, oipAReads an outer-membrane gene that amplifies inflammation in the stomach wall.An oipA-positive strain suggests a more inflammatory infection, one input into the panel's overall aggression picture.
- Virulence Factor, vacAReads the toxin gene whose s1/m1 version damages stomach-lining cells and helps the bacterium evade your immune system.The vacA s1/m1 pattern carries the clearest measured link in this panel to peptic ulcer and gastric cancer.
- Virulence Factor, virBReads part of the molecular syringe the bacterium uses to inject its cagA protein into your cells.virB signals an intact delivery system that lets an aggressive strain actually deliver its cagA payload.
- Virulence Factor, virDReads another component of the injection machinery that carries cagA and other substances into stomach cells.virD complements virB, indicating the secretion apparatus a cagA strain needs to cause damage is assembled.
- Amoxicillin ResistanceLooks for changes in the bacterial protein that amoxicillin targets, a backbone of nearly every eradication regimen.Resistance is uncommon but, when genuinely present, strongly predicts failure; the DNA signal is less reliable here than for clarithromycin.
- Clarithromycin ResistanceDetects the mutation that makes the most commonly prescribed H. pylori antibiotic stop working.Resistance here predicts that standard triple therapy will likely fail, steering treatment toward a bismuth-based quadruple regimen instead.
- Fluoroquinolones ResistanceDetects mutations that blunt levofloxacin-type antibiotics, a common second-line eradication option.Resistance here rules out fluoroquinolone-based rescue therapy before it is tried, sparing you a likely failed course.
- Tetracycline ResistanceScreens for the rare mutation that weakens tetracycline, a component of bismuth quadruple therapy.Resistance is unusual, and a clear result supports keeping tetracycline in a quadruple rescue regimen with confidence.
About H. Pylori Profile
More than 40% of the world's population carries Helicobacter pylori, a bacterium that quietly settles into the stomach lining. In most people it does little. In others it drives ulcers and, over decades, gastric cancer.
What separates those outcomes often comes down to two things: which strain you carry and whether the drugs meant to remove it still work. A yes-or-no test answers neither question. This stool profile is built to answer both.
What This Panel Reveals
The panel tells one connected story in three parts: is the bacterium there, how dangerous is your particular strain, and will the usual antibiotics clear it. Each layer is read from the same stool sample using a lab method that reads bacterial DNA (called PCR).
Confirming the Infection
The first result simply establishes whether Helicobacter pylori is actively living in your stomach. This matters on its own. Detecting and removing the bacterium roughly halves later gastric cancer risk in infected people, and treating it promptly after an ulcer sharply lowers the chance the ulcer returns. Modern stool DNA testing is accurate for this, with one stool PCR study detecting infection at about 96% sensitivity and 99% specificity.
The Strain's Aggression
Not all strains behave the same, and the virulence genes map how harmful yours may be. The two best-studied are cagA, a gene for a protein the bacterium injects into your stomach cells to stoke inflammation, and vacA, a gene for a toxin that damages the lining. Carrying a cagA-positive strain has been linked to about 2.5 times the odds of gastric cancer versus gastritis alone, and the vacA s1/m1 version carries the clearest measured link in this group, with adjusted odds around 2.0 for ulcer and 6.6 for gastric cancer in one 921-person study.
The remaining genes fill in the picture. Two of them (virB and virD) build the molecular syringe that lets cagA reach your cells, while babA helps the bacterium grip the lining, and oipA, dupA, and iceA modify how much inflammation and ulceration follow. On their own, single genes are informative but not deterministic. High-risk combinations matter more than any one marker, and one recent analysis estimated roughly 11 times the gastric cancer odds for a strain carrying cagA, vacA s1/m1, and several partner genes together.
Whether the Drugs Will Work
The resistance markers are the most immediately actionable layer. They read the specific bacterial mutations that make four antibiotic classes fail: clarithromycin, fluoroquinolones (such as levofloxacin), amoxicillin, and tetracycline. Clarithromycin is the linchpin. When its resistance mutation is present, standard triple therapy fails far more often, with one cohort eradicating just 38.5% of resistant infections versus 97.2% of susceptible ones, and a global analysis finding resistant strains nearly seven times more likely to fail treatment.
How to Read Your Results Together
The value of this panel is in the combination. Infection status sets the stage, resistance markers pick the drug, and virulence genes gauge how much urgency your case carries. A few patterns are worth recognizing.
| Pattern | What it suggests |
|---|---|
| Bacterium detected, clarithromycin resistance present | Standard triple therapy is likely to fail; a bismuth-based quadruple regimen is usually preferred from the start. |
| Bacterium detected, cagA and vacA s1/m1 present | A more aggressive strain tied to higher ulcer and cancer risk; confirming eradication and follow-up matters more. |
| Bacterium detected, no resistance markers found | First-line therapy has a good chance of working, and treatment can proceed with more confidence. |
| Bacterium not detected | No active infection; persistent stomach symptoms likely have another cause worth investigating. |
What to Do with Your Results
A positive infection result is a reason to treat, even without symptoms. Bring the resistance findings to a clinician who can match the regimen to them, since choosing therapy guided by susceptibility outperforms guessing, with one meta-analysis showing about a 14% relative improvement in first-line cure over clarithromycin-based triple therapy. That edge is clearest when local clarithromycin resistance is high and largely disappears against bismuth quadruple therapy, now a preferred first-line regimen. If a strong-risk strain shows up, that is a case for endoscopic evaluation, especially with a family history of gastric cancer.
Serial testing closes the loop. After finishing antibiotics, retest (waiting at least four weeks off treatment) to confirm the bacterium is actually gone rather than assuming it. Delay carries a real cost: recurrent-ulcer risk climbs steadily the longer eradication is postponed. Companion blood work such as ferritin, vitamin B12, and a blood count can catch the iron deficiency, low B12, and slow bleeding that chronic infection sometimes causes.
When Results Can Be Misleading
A few factors distort the whole panel at once. Recent antibiotics, bismuth, and acid-suppressing medications (proton pump inhibitors) lower the bacterial load in the stomach and can produce a false negative, so results are cleanest after a washout period your clinician defines, typically stopping proton pump inhibitors for two weeks and antibiotics or bismuth for four weeks. Low bacterial load also makes the virulence read less reliable. And the resistance genotyping is most trustworthy for clarithromycin and fluoroquinolones; for amoxicillin and tetracycline the DNA signal matches real-world resistance less consistently, so a clean result there is reassuring but not absolute.